PointCheck for Low White Blood Cell Count
What You Need to Know Before You Apply
What is the purpose of this trial?
This a study about the usability of PointCheck a novel non-invasive technology for monitoring chemotherapy-induced neutropenia.The study will include patients with cancer visiting the outpatient hematology clinic for their standard of care chemotherapy administration. A final sample size of 90 oncologic outpatients will be enrolled and studied with the technology.The main objective is to evaluate the usability of PointCheck. Secondary outcomes include a preliminary assessment of PointCheck diagnostic accuracy and precision.For this, study subjects will be tested twice with PointCheck during the same session and the usability in an at-home simulated environment by naïve users will be evaluated
Who Is on the Research Team?
Mark Sloan, MD
Principal Investigator
Boston Medical Center
Are You a Good Fit for This Trial?
This trial is for adults over 18 with hematological cancers or breast cancer, who are undergoing high/intermediate risk neutropenia-inducing chemotherapy. They must understand the study and consent to participate. Excluded are those with uncontrolled low blood pressure, significant hand tremors or abnormalities, circulating tumor cells in labs, leukemia, certain rheumatologic conditions affecting circulation, or any condition that may risk their safety or affect results.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are tested twice with PointCheck during the same session and usability in an at-home simulated environment is evaluated
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- PointCheck
Find a Clinic Near You
Who Is Running the Clinical Trial?
Leuko Labs, Inc.
Lead Sponsor
National Cancer Institute (NCI)
Collaborator